Clinical trial · Expanded Access
Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors
NCT06362590CI-TRIAL-00091103availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 9, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260909-000002
Summary
Brief summary (as posted)
The purpose of this study is to provide the option of Ladiratuzumab Vedotin treatment to eligible patients in studies SGNLVA-005.
Conditions
Conditions (0)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
Data not yet available
No condition recorded.
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ladiratuzumab vedotin | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
Show eligibility criteria text
Inclusion Criteria: \- Exclusion Criteria: \-
References
Publications (0)
Data not yet available
No reference posted for this study.